Durability of the BNT162b2 XBB:1.5-adapted vaccine against JN.1 hospitalisation in Europe, October 2023 to August 2024: A test-negative case-control study using the id.DRIVE platform

Hannah R. Volkman ,Leonie de Munter, Jennifer L. Nguyen, Thao M. P. Tran, Marianna Mitratza, Cátia Marques, Laura Choi, Srinivas Valluri, Jingyan Yang, Andrés Antón, Irma Casas, Eduardo Conde-Sousa, Laura Drikite, Beate Grüner, Giancarlo Icardi, Gerrit Luit ten Kate, Charlotte Martin, Ainara Mira-Iglesias, Alejandro Orrico-Sánchez, Susana Otero-Romero, Gernot Rohde, Luis Jodar, John M. McLaughlin & Kaatje Bollaerts.

PLOS One
https://doi.org/10.1371/journal.pone.0342382

Leave a Reply

Your email address will not be published. Required fields are marked *